CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS

ONC201, an anti-cancer DRD2 antagonist and ClpP agonist, is in Phase II trials for adult H3 K27M-mutant diffuse midline gliomas. In adults, the recommended phase 2 dose (RP2D) of 625mg ONC201 once a week has been established as a biologically active dose that is well tolerated. Radiographic regressi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Gardner, Sharon, Koschmann, Carl, Tarapore, Rohinton S, Allen, Jeffrey, Zaky, Wafik, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Khatib, Ziad, Aguilera, Dolly, MacDonald, Tobey, Fouladi, Maryam, McGovern, Susan, Mueller, Sabine, Kline, Cassie, Vitanza, Nicholas, Lu, Guangrong, Allen, Joshua, Khatua, Soumen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Clinical Trials: Non-Immunologic
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650473/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.182
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg